Business
Sensus Healthcare Sells its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash
Sale permits Sensus to focus on the core dermatology market while providing capital for channel expansion BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) --
About this update from Sensus Healthcare, Inc.
[{"type":"text","content":"Sale permits Sensus to focus on the core dermatology market while providing capital for channel expansion BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has sold its Sculptura™ assets to Empyrean Medical Systems for $15 million in cash. The sale, completed on February 25, 2022, included inventory of Sculptura™ systems and parts, in addition to all related intellectual property. “Sculptura will be in excellent, capable hands under the ownership of Empyrean, and we wish them all the best in their endeavors with this fabulous technology,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “Given the rebound in sales of Sensus’ SRT systems and in the dermatology market as a whole, we believe our resources are best focused on our core dermatology business. Sensus has already begun to expand its dermatology product offerings with the recent additions of the TransDermal™ Infusion non-invasive drug delivery system as well as Sensus Laser Systems, and we intend to use the proceeds from this sale to expand even further.” “We are thrilled to acquire and add the Sculptura™ to Empyrean’s arsenal of cancer-vanquishing products and solutions,” said Kal Fishman, chairman and chief executive officer of Empyrean Medical Systems. “It is a natural continuum from Sensus’ line of innovations and patient-centric solutions, which will allow us to bring this disruptive technology to patients and clinicians worldwide. We are excited to launch Sculptura™ under Empyrean’s Morpheus™ brand, which will provide clinicians with a state-of-the-art robotically assisted Beam Sculpting™ treatment modality for their cancer patients worldwide. Empyrean’s mission is to innovate and deliver paradigm-shifting treatment technologies for our patients, and launching Morpheus™ this year is our first act on this journey.” The Sculptura™ system provides targeted Directional Anisotropic Radiation Therapy (ART™) and brachytherapy utilizing proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sculptura received U.S. Food and Dru...